nuGenerex concall Oct 8 at 8am Closing of licen
Post# of 36566
(Total Views: 492)
Posted On: 10/02/2020 1:02:38 PM
nuGenerex concall Oct 8 at 8am
Closing of licensing deal
update on vaccine dev
application on Nasdaq update
MIRAMAR, Fla., Oct. 02, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology ( http://nugenerexio.com ) is pleased to announce that the company will hold a shareholder conference call on Thursday October 8 th at 8:00 AM. CEO Joseph Moscato will update its shareholders on its ongoing development program with the Ii-Key-SARS-CoV-2 vaccine, strategy for advancing the COVID-19 vaccine for U.S. and international markets, and details on the scheduled closing of the licensing, commercialization, and distribution deal with Bintai. Mr. Moscato will also discuss the planned SEC filings which will enable the company to list its securities on the Nasdaq stock exchange directly.
Joseph Moscato, CEO of NGIO stated, “As we are scheduled to close the licensing deal with Bintai, we wanted to hold this shareholder call next Thursday after the deal is scheduled to close, and we receive the upfront licensing payment. On the call I will provide our shareholders with specifics on the Bintai deal as well as discussions with other potential partners that will further expand the clinical development and commercialization of our Ii-Key vaccine internationally. I will also discuss our newly formed COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to help guide the clinical development program for the Ii-Key-SARS-CoV-2 vaccine with a special emphasis on development of a safe and effective vaccine for the pediatric population including children and adolescents. We are excited about the planned application for listing of NGIO on Nasdaq, which will allow the management team to execute on its strategy. Generex Biotechnology Corp will remain the parent company of NuGenerex Immuno-Oncology after the listing of NGIO, this will add substantial value to Generex (GNBT) shareholders.”
Details on the October 8 th shareholders conference call will be announced in a future press release.
Closing of licensing deal
update on vaccine dev
application on Nasdaq update
MIRAMAR, Fla., Oct. 02, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology ( http://nugenerexio.com ) is pleased to announce that the company will hold a shareholder conference call on Thursday October 8 th at 8:00 AM. CEO Joseph Moscato will update its shareholders on its ongoing development program with the Ii-Key-SARS-CoV-2 vaccine, strategy for advancing the COVID-19 vaccine for U.S. and international markets, and details on the scheduled closing of the licensing, commercialization, and distribution deal with Bintai. Mr. Moscato will also discuss the planned SEC filings which will enable the company to list its securities on the Nasdaq stock exchange directly.
Joseph Moscato, CEO of NGIO stated, “As we are scheduled to close the licensing deal with Bintai, we wanted to hold this shareholder call next Thursday after the deal is scheduled to close, and we receive the upfront licensing payment. On the call I will provide our shareholders with specifics on the Bintai deal as well as discussions with other potential partners that will further expand the clinical development and commercialization of our Ii-Key vaccine internationally. I will also discuss our newly formed COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to help guide the clinical development program for the Ii-Key-SARS-CoV-2 vaccine with a special emphasis on development of a safe and effective vaccine for the pediatric population including children and adolescents. We are excited about the planned application for listing of NGIO on Nasdaq, which will allow the management team to execute on its strategy. Generex Biotechnology Corp will remain the parent company of NuGenerex Immuno-Oncology after the listing of NGIO, this will add substantial value to Generex (GNBT) shareholders.”
Details on the October 8 th shareholders conference call will be announced in a future press release.
(3)
(0)